At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Hyperpolarised MRI (device), Sodium MRI (device), Deuterium metabolic imaging (DMI) MRI (device)
- How long the study runs
- Study runs about 36 months (dates as stated)
- About the drug or intervention
- Hyperpolarised MRI — device: Hyperpolarised 13C-pyruvate injection while laying in the MRI scanner. · Sodium MRI — device: MRI procedure as a regular MRI scan, the only change is us using a different sort of equipment so we are able to detect sodium. · Deuterium metabolic imaging (DMI) MRI — device: Drink of a sugar drink 90min before the MRI scan.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 30
- Started
- 2023-01-01
- Last checked
- 2024-12
Plain English Summary
What is this study?
- • Testing a new treatment for kidney cancer
- • NA - 30 participants
- • The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with kidney cancer
Where?
- • Cambridge - University Department of Radiology
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The aim of this study is to develop techniques for non-invasive imaging of biology in participants with benign or malignant renal masses based on the novel scanning MRI techniques, including recently invented Hyperpolarised MRI, deuterium metabolic imaging and sodium MRI. This imaging study will: 1) acquire imaging data from human tissues following the injection of hyperpolarised 13C pyruvate and use 13C-MRI to monitor changes in the ratio of 13C-lactate to 13C-pyruvate; 2) acquire imaging data from human tissues using Sodium MRI or 3) acquire imaging data from human tissues following the oral consumable of deuterated glucose. Data acquired during this physiological study will be used to optimise future imaging protocols.In the UK and possibly in other countries, there are some patients with renal masses that are over treated or undergo unnecessary procedures such as surgery or biopsies, as they are thought to have a malignant tumour or a more aggressive tumour but after the procedure it is found that the mass was benign. The aim of this study is to determine whether one or all of these imaging techniques can differentiate between benign and malignant renal masses with the view to developing the techniques further and hopefully reducing the need for over treatment or unnecessary procedures in patients with benign masses.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Over 18 years old
- ✓Able to and provide written agreement to take part to participate
- ✓If female, postmenopausal or if women of child bearing potential (WOCBP) using a suitable contraception
- ✓If male, using a suitable contraceptive method for the duration of the study
- ✓Radiologically suspected or pathologically confirmed benign or malignant kidney masses, as determined by standard...
Who cannot take part
- ✗safety concern or inability to tolerate MRI
- ✗Pregnant or actively breast-feeding woman
- ✗If using an intrauterine contraceptive device (IUCD) as a method of contraception the device should be MRI safe at 3...
- ✗Clinically significant heart, lung or neurological diseases as determined by the investigators
- ✗Laboratory abnormalities that may impact on the study results
See the full criteria
Where Is This Study? (1 UK site)
University Department of Radiology
Cambridge CB2 0QQ, United Kingdom
How to Get in Touch
Ines Horvat-Menih, MD
Sponsor contactCONTACT
Marta Wylot, PhD
Sponsor contactCONTACT